Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)

Sep. 2026Pharmacy Updates

Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).

This drug is being recalled because the product may be superpotent. Using a superpotent product can cause hyperthyroidism (overactive thyroid) with symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, or heart rhythm disturbances.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Thyroid Tablet or are experiencing any problems that may be related to receiving the product, you should not stop taking the product without talking to your doctor.

As of Aug. 21, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Vitruvias Therapeutics Inc. at 256-239-9373. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. CST.
  • Email Vitruvias Therapeutics Inc. at safety@vitruvias.com.

Recent Announcements

Clinical workflow changes through Epic®

Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.
Oct. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Oct. 2026Important Notices

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Oct. 2026Education/Webinars